Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 3, 2022
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
[ Thu, Nov 03rd 2022
] - WOPRAI
Salveen Richter Maintained (SRPT) at Strong Buy with Increased Target to $171 on, Nov 3rd, 2022
Salveen Richter of Goldman Sachs, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $152 to $171 on, Nov 3rd, 2022.
Salveen has made no other calls on SRPT in the last 4 months.
There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 1 agrees with Salveen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022
This is the rating of the analyst that currently disagrees with Salveen
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022
